Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Dipna Pharmachem's FCF Margin % or its related term are showing as below:
BOM:543594'
s FCF Margin % Range Over the Past 10 Years
Min: -21 Med: -7.86 Max: 3.85
Current: -14.7
During the past 7 years, the highest FCF Margin % of Dipna Pharmachem was 3.85%. The lowest was -21.00%. And the median was -7.86%.
BOM:543594's FCF Margin % is ranked worse than 79.16% of 667
companies
in the Healthcare Providers & Services industry
Industry Median: 3.15
vs BOM:543594: -14.70
The historical data trend for Dipna Pharmachem's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Dipna Pharmachem's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dipna Pharmachem FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dipna Pharmachem's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Dipna Pharmachem's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dipna Pharmachem (BOM:543594) has a FCF Margin % of -1.23% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Dipna Pharmachem and its competitors. According to the industry distribution chart, Dipna Pharmachem ranks #528 out of 667 companies in the Healthcare Providers & Services industry, placing it in the top 79.2%.
Is Dipna Pharmachem's FCF Margin % too high?
Dipna Pharmachem's current FCF Margin % is -1.23%. Based on the distribution chart, Dipna Pharmachem ranks #528 out of 667 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Dipna Pharmachem has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dipna Pharmachem's FCF Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Dipna Pharmachem ranks #528 out of 667 companies for FCF Margin %. This places Dipna Pharmachem in the lower half of its industry. The industry median FCF Margin % is 3.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.15, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Dipna Pharmachem and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dipna Pharmachem's current FCF Margin % is -1.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dipna Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Dipna Pharmachem (BOM:543594) is currently considered Possible Value Trap. The stock's GF Value™ is ₹9.16, compared to a current price of ₹4.89 — trading 46.6% below its estimated fair value. The current FCF Margin % is -1.23%. Dipna Pharmachem's overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Dipna Pharmachem (BOM:543594), the current FCF Margin % is -1.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dipna Pharmachem (BOM:543594) Overvalued in 2026?
Based on GuruFocus' analysis, Dipna Pharmachem stock appears to be undervalued.
The current stock price of ₹4.89 is trading 46.6% below its estimated GF Value™ of ₹9.16.
GuruFocus considers Dipna Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:543594:
FCF Margin %: -1.23%
GF Value™: ₹9.16 vs. price of ₹4.89 (46.6% below fair value)
No single metric tells the full story. See the BOM:543594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dipna Pharmachem Ltd is engaged in the trading and distribution of a wide range of pharmaceutical raw materials which is also known as APIs (Active Pharmaceutical Ingredients), Excipient and chemical formulation products. The company's product portfolio comprises of Hydrocortisone Acetate, Aceclofenac, Asprin, Levofloxacin, and others.
62GF Score
Get the complete analysis for BOM:543594
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543594 has been successfully added to your 
